Abstract
To the Editor:— I have read with interest a number of Clinical Notes inThe Journalin the past 18 months on antibiotic-related respiratory depression ( 190 :421, 1964; 194 :298, 1965; 196 :181, 1966). Particularly disturbing is the consistency of the theme of reports of apnea induced by the closely related polypeptide antibiotics polymyxin B sulfate and sodium colistimethate. In each of these reports the patients were receiving large or maximally recommended doses of these agents; there was indication of neurologic dysfunction (dysphagia, circumoral paresthesias, blurred vision) hours to days prior to sustained apnea. In spite of symptoms of neurotoxicity, drug administration was continued in unchanged dosages. Two of the patients were azotemic at the inception of therapy (which is in itself an indication for lowered dosage), and the third became azotemic during treatment. In one case, serum concentration of the drug at the time of the apneic episode was
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
